132712-71-1

Basic information

• Product Name: 3-methyl-1H-pyrazol-5-ol
• Synonyms: 3-methyl-1H-pyrazol-5-ol;5-Methyl-2H-pyrazol-3-ol;1H-Pyrazol-5-ol, 3-Methyl-
• CAS NO: 132712-71-1
• Molecular Formula: C₄H₆N₂O
• Molecular Weight: 98.10324
• EINECS: 203-565-3
• Mol File: 132712-71-1.mol
• Article Data: 17

Chemical Properties

• Melting Point: 220-224℃
• Boiling Point: 309.7°C at 760 mmHg
• Flash Point: 141.1°C
• Appearance: /
• Density: 1.107g/cm³
• Vapor Pressure: 0.000345mmHg at 25°C
• Refractive Index: 1.475
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-methyl-1H-pyrazol-5-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-1H-pyrazol-5-ol(132712-71-1)
• EPA Substance Registry System: 3-methyl-1H-pyrazol-5-ol(132712-71-1)

Safety Data

• Safety Statements: S24/25:
• Hazardous Substances Data: 132712-71-1(Hazardous Substances Data)

Usage

General Description

3-methyl-1H-pyrazol-5-ol is an organic compound that falls under the category of pyrazoles. Pyrazoles are a class of compounds containing a 5-membered aromatic ring, with two nitrogen atoms, and are often used in the development of various pharmaceuticals and agrochemicals. The exact properties of 3-methyl-1H-pyrazol-5-ol can vary, but like all pyrazoles, it is expected to be relatively stable but may present safety or health hazards if mishandled. The compound's use is generally confined to specialist or laboratory settings but it can serve as a building block or reagent in the synthesis of more complex molecules.

InChI:InChI=1/C4H6N2O/c1-3-2-4(7)6-5-3/h2H,1H3,(H2,5,6,7)

Upstream product

• 161374-07-8 ethyl 4-(4-methoxyphenyl)-6-methyl-1,2,3,4-tetrahydropyrimidin-2-one-5-carboxylate 
• 5948-71-0 4-(4-chlorophenyl)-5-(ethoxycarbonyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one 
• 123043-88-9 5-ethoxycarbonyl-4-phenyl-6-methyl-3,4-dihydropyrimidine-2(1H)-thione 
• 185023-34-1 5-carboethoxy-6-methyl-4-(4-methylphenyl)-1H-pyrimidin-2-thione 
• 113697-57-7 5-(ethoxycarbonyl)-4-(4-methoxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-thione 
• 154866-92-9 ethyl 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-thioxopyrimidine-5-carboxylate 
• 123237-03-6 ethyl 6-methyl-4-phenyl-3,4-dihydropyrimidin-2(1H)-one-5-carboxylate 
• 299949-24-9 ethyl 6-methyl-2-oxo-4-p-tolyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 105-45-3 acetoacetic acid methyl ester 
• 141-97-9 ethyl acetoacetate 
• 302-01-2 hydrazine 

Downstream Products

• 85220-06-0 5-Hydroxy-3-methyl-pyrazole-1-carboxylic acid p-tolylamide 
• 91614-52-7 2-benzyl-3-ethoxycarbonyl-7-methylpyrazolo<5,1-b><1,3>oxazin-5(5H)-one 
• 91614-65-2 3-benzyl-2-ethoxycarbonyl-5-methylpyrazolo<1,2-a>pyrazole-1,7(1H,7H)-dione 
• 91614-73-2 3-benzyl-2-ethoxycarbonyl-7-methylpyrazolo<1,2-a>pyrazole-1,5(1H,5H)-dione 
• 91614-55-0 3-ethoxycarbonyl-7-methyl-2-phenylpyrazolo<5,1-b><1,3>oxazin-5(5H)-one 
• 91614-68-5 2-ethoxycarbonyl-5-methyl-3-phenylpyrazolo<1,2-a>pyrazole-1,7(1H,7H)-dione 
• 128671-08-9 5-Methyl-2-[2-oxo-1-(p-tolyl-hydrazono)-propyl]-2,4-dihydro-pyrazol-3-one 
• 128671-07-8 5-Methyl-2-{1-[(4-nitro-phenyl)-hydrazono]-2-oxo-propyl}-2,4-dihydro-pyrazol-3-one 
• 85220-05-9 5-Hydroxy-3-methyl-pyrazole-1-carboxylic acid (3-chloro-phenyl)-amide 
• 85220-07-1 5-Hydroxy-3-methyl-pyrazole-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide 
• 128670-96-2 3-(4-Chloro-phenyl)-6-methyl-1-phenyl-1H-pyrazolo[5,1-c][1,2,4]triazole 
• 1068515-75-2 4-(4-(diethylamino)benzylidene)-3-methyl-1H-pyrazol-5(4H)-one 
• 433956-14-0 4,4'-((4-(diethylamino)phenyl)methylene)bis(5-methyl-1H-pyrazol-3(2H)-one) 
• 51395-52-9 4-bromo-3-methyl-<1H>-pyrazolin-5-one 

Relevant articles and documents

Meglumine catalyzed one pot synthesis of new fluorescent 2-amino-4-pyrazolyl-6-aryldiazenyl-4H-chromene-3-carbonitriles

Meglumine, a biodegradable basic organo-catalyst has been efficiently explored for the one-pot synthesis of new fluorescent 2-amino-4-(5-hydroxy-3-methyl-1H-pyrazol-4-yl)-6-aryldiazenyl-4H-chromene-3-carbonitriles in an aqueous medium at room temperature. The synthesized compounds were found highly fluorescent when screened for photoluminescence properties. The planar structure equipped with substituted aryldiazenyl group led to the extension of conjugation that facilitated fluorescence emission in the visible region with a large stokes shift of 290–294 nm. The novelty of work is a synthesis of highly conjugated molecular assembly, high yield in shorter reaction time, energy efficiency, atom economy, utilization of water as a universal green solvent and meglumine as an eco-benign organo-catalyst.

“On-water” one-pot four-component synthesis of novel 1H-furo[2,3-c]pyrazole-4-amine derivatives

A catalyst-free, simple and green protocol has been accomplished for the synthesis of novel 1H-furo[2,3-c]pyrazole-4-amines in a one-pot four-component domino reaction involving hydrazines, ethyl acetoacetate, aromatic amines and phenylglyoxal monohydrate in water. The protocol presented herein describes in situ generated pyrazolone as intermediate reactants with phenylglyoxal monohydrate in a Knoevenagel condensation followed by a Michael addition of amine, intramolecular cyclization, dehydration and the resulting to the title compound. It was observed that in this protocol bis(pyrazole-5-ols) are formed with amines bearing strong electron withdrawing groups under similar reaction conditions instead of the expected products. The reaction merits the use of water as solvent, no additive catalyst, easy workup, easy purification of products by non-chromatography and provides high yield of products with good purity.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.